Corporate venture capital explained: what CVC is, how it evolved from the 1960s into a $500bn+ market, and why corporates invest. Part 1 of Breslin AG’s series.
Higher US yields, a stronger euro and ECB-Fed divergence are reshaping private equity and venture allocation. Why USD investors should look to Europe.
A practical view on how Swiss and German pension funds engage with private equity, the quantitative caps that govern them, and the secondary market that keeps pension, endowment and charity portfolios moving.
Private Equity in DACH Pensions: Caps, Allocators and the Secondary Market Read Post »
How DACH sellers of Non-Cyclical, Industrial, Life Science and Energy portfolios can minimise secondary market discounts and secure the best return.
DACH insurers are reviewing private equity holdings in healthcare, life sciences, pharma, agri and technology. The secondary market offers liquidity, portfolio repositioning and targeted private equity placements.
Secondary Market Opportunities for DACH Insurers Read Post »
Private equity secondaries in 2026 are being reshaped by tighter pricing, more sophisticated GP-led deals, and changing LP liquidity needs. We examine the key trends, valuation shifts, and what has changed for investors.
LP and GP Secondary Market Strategies in 2026: Trends, Pricing and What’s Changed Read Post »
